Review of senolytic and senomorphic strategies for skin senescence
This review describes cellular senescence in skin and proposes two gerotherapeutic approaches: senolytics that clear persisting senescent cells, and senomorphics that modulate their inflammatory secretions without killing the cells. [1]
Automatic summary · not editorially reviewed
The key findings
Senescent keratinocytes, fibroblasts and melanocytes can release pro-inflammatory mediators and other factors, collectively termed the senescence-associated secretory phenotype (SASP). [1]
Senolytics selectively eliminate senescent cells, while senomorphics modulate or suppress SASP activity without inducing senescent cell death. [1]
The review considers the mechanisms of skin senescence, evidence for both approaches and future directions for integrating senotherapeutics into dermatology. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Skin cells and dermatologic conditions discussed in a review
- Summary based on
- Study abstract
- Original publication
- July 8, 2026
Senescent skin cells and their secretions
The review states that cellular senescence is a central mechanism in cutaneous aging, impaired regeneration and many skin diseases. Senescence first evolved as protection against malignant transformation and to support wound repair, but becomes maladaptive when senescent cells persist. Senescent keratinocytes, fibroblasts and melanocytes can release pro-inflammatory mediators and other factors, collectively called the senescence-associated secretory phenotype (SASP). According to the review, these factors may degrade extracellular matrix components, disrupt pigmentary balance and impair barrier function. Senescent cells resist conditions that kill non-senescent cells and are generally removed by the immune system; persisting ones can become increasingly pro-inflammatory and fibrotic, perhaps due to accumulating DNA damage.
Supporting source [1]
Senolytics versus senomorphics in skin
The review describes two proposed geroscience-based therapeutic paradigms (gerotherapeutics). Senolytics selectively eliminate senescent cells; senomorphics modulate or suppress SASP activity without inducing senescent cell death. The review notes that interfering with regulators of senescent cell formation such as p16, retinoblastoma protein (pRB), p53 or p21 can be detrimental because transient senescence protects wound healing and cancer suppression. Senolytics instead act by clearing already formed, persisting, tissue-damaging senescent cells and are described as offering the potential to delay, prevent, alleviate or treat aged or fibrotic skin. Because senescent cells take days to weeks to fully form and cannot divide, senolytics can be given intermittently, for example for brief intervals every 2 weeks or once a month; senomorphics generally need continuous or more frequent administration. Some agents are both senolytic and senomorphic.
Supporting source [1]
Review scope and expected translation steps
The review considers the mechanistic basis of senescence in skin, the evidence for both therapeutic approaches and future directions for integrating senotherapeutics into regenerative and aesthetic dermatology. It states that skin is particularly relevant for these approaches because of its accessibility, visible aging markers and ability to serve as a translational platform for systemic gerotherapeutic interventions. Advances in cutaneous biomarkers, topical delivery systems and AI-assisted patient stratification are expected to accelerate translation into clinical practice. The abstract does not report trial results, effect sizes or safety data for specific agents.
Supporting source [1]
How to interpret this
This is an abstract; the full text was not reviewed. The abstract reports no trial results, effect sizes, safety data or specific agents, and the described therapeutic approaches are proposed paradigms, not validated treatments.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Haykal D, Flament F, Garibyan L, Lee K, Escot J, Gueniche A, Kirkland J. · europepmc.org · July 8, 2026